case_images: PMC5869552_01
case_images: Overview of the laboratory results at the time of the patient's initial presentation in 2013, the results at the end of 2016 leading to the treatment decision with elbasvir/grazoprevir, during, at the end, and 12 weeks after (SVR 12) elbasvir/grazoprevir treatment. a Overview and development of liver values. b Overview and development of kidney values. c Overview and development of hepatitis C viremia.
case_images: crg-0012-0092-g01.jpg
case_images: PMC5869552_01_crg-0012-0092-g01.jpg
case_images: F1
case_images: In the end of 2016, the patient presented with progressive liver disease graded Child A6, MELD 13, demonstrated by elevated liver enzymes (Fig. 1a; Table 2), a FibroScan of 16.5 kPa, CAP 300 dB/m, and an ultrasound showing progressive fibrotic changes in the liver. Table 2). The hepatitis C viremia decreased over the first few weeks, with an undetectable virus content 1 month after therapy induction (Fig. 1c; Table 2). During the first few weeks the patient's kidney values increased but returned to a stable level towards the end of therapy (Fig. 1b; Table 2).